134 related articles for article (PubMed ID: 8390969)
1. In vivo accumulation of sodium pump inhibitor by normal and uremic erythrocytes.
Gallice P; Lai E; Brunet P; Berland Y; Elsen R; Crevat A
Int J Artif Organs; 1993 Mar; 16(3):120-2. PubMed ID: 8390969
[TBL] [Abstract][Full Text] [Related]
2. Separation from uremic body fluids and normal urine of Na+, K+-ATPase inhibitor.
Gallice P; Monti JP; Braguer D; Durand C; Manchon H; Murisasco A; Crevat A
Adv Exp Med Biol; 1987; 223():215-8. PubMed ID: 2833847
[No Abstract] [Full Text] [Related]
3. 23Na nuclear magnetic resonance study of Na+-K+ pump inhibition by a fraction from uremic toxins.
Gallice P; Monti JP; Baz M; Murisasco A; Crevat A
Clin Chem; 1988 Oct; 34(10):2044-7. PubMed ID: 2844439
[TBL] [Abstract][Full Text] [Related]
4. Sodium pump activity in uremic erythrocytes: a microcalorimetric study.
Gallice P; Kovacic H; Baz M; Berland Y; Elsen R; Sari JC; Crevat A
Int J Artif Organs; 1992 Mar; 15(3):135-8. PubMed ID: 1325947
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of alteration of sodium potassium pump of erythrocytes from patients with chronic renal failure.
Cheng JT; Kahn T; Kaji DM
J Clin Invest; 1984 Nov; 74(5):1811-20. PubMed ID: 6094614
[TBL] [Abstract][Full Text] [Related]
6. Ascorbic acid derivatives in two different fractions of uremic toxins.
Gallice PM; Monti JP; Braguer DL; Baz M; Elsen RE; Berland YF; Crevat AD
Int J Artif Organs; 1991 Dec; 14(12):754-8. PubMed ID: 1783448
[TBL] [Abstract][Full Text] [Related]
7. High-resolution NMR studies of transmembrane cation transport in uremic patients.
Monti JP; Baz M; Elsen R; Berland YF; Crevat AD
Biochim Biophys Acta; 1990 Aug; 1027(1):31-40. PubMed ID: 2168751
[TBL] [Abstract][Full Text] [Related]
8. Uremic toxins and the elusive middle molecules.
Schoots A; Mikkers F; Cramers C; de Smet R; Ringoir S
Nephron; 1984; 38(1):1-8. PubMed ID: 6472528
[No Abstract] [Full Text] [Related]
9. Erythrocyte transport of middle molecular substances.
Gajdos M; Spustová V; Geryková M; Dzúrik R
Proc Eur Dial Transplant Assoc; 1981; 18():183-7. PubMed ID: 7329966
[TBL] [Abstract][Full Text] [Related]
10. [Study of middle molecules with positive reaction to ninhydrin present in uremic and normal blood and their isolation].
Buzio C; Dall'Aglio PP; Delmonte G; Montagna G; Migone L
Minerva Nefrol; 1979; 26(1):45-8. PubMed ID: 471320
[No Abstract] [Full Text] [Related]
11. Ion-pair high-performance liquid chromatography profiling of a uremic toxin fraction.
Gallice P; Monti JP; Le Gall JM; Crevat A; Murisasco A
J Chromatogr; 1987 Nov; 422():263-6. PubMed ID: 3437013
[No Abstract] [Full Text] [Related]
12. A compound from uremic plasma and from normal urine isolated by liquid chromatography and identified by nuclear magnetic resonance.
Gallice P; Monti JP; Crevat A; Durand C; Murisasco A
Clin Chem; 1985 Jan; 31(1):30-4. PubMed ID: 3965216
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte Na,K pump in uremia. Acute correction of a transport defect by hemodialysis.
Izumo H; Izumo S; DeLuise M; Flier JS
J Clin Invest; 1984 Aug; 74(2):581-8. PubMed ID: 6086716
[TBL] [Abstract][Full Text] [Related]
14. Uremic middle molecules exist and are biologically active.
Bergström J; Fürst P; Zimmerman L
Clin Nephrol; 1979 May; 11(5):229-38. PubMed ID: 455821
[No Abstract] [Full Text] [Related]
15. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
Ringoir SM; van Landschoot N; de Smet R
Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
[TBL] [Abstract][Full Text] [Related]
16. Chemical analytic approaches to the definition of uremic toxins.
Furst P; Bergstrom J; Gordon A; Zimmermann L
Ateneo Parmense Acta Biomed; 1975; 46(5):307-16. PubMed ID: 1232992
[TBL] [Abstract][Full Text] [Related]
17. Influence of uremic middle molecules on blood cells.
Ota K; Sanaka T; Agishi T; Nakajima O
Artif Organs; 1980 May; 4(2):113-5. PubMed ID: 7396763
[TBL] [Abstract][Full Text] [Related]
18. Uremic middle molecules in non-dialyzed azotemic patients: relation to symptoms and clinical biochemistries.
Asaba H; Alvestrand A; Bergström J; Fürst P; Yahiel V
Clin Nephrol; 1982 Feb; 17(2):90-5. PubMed ID: 7067171
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet function by uremic middle molecules.
Bazilinski N; Shaykh M; Dunea G; Mamdani B; Patel A; Czapek E; Ahmed S
Nephron; 1985; 40(4):423-8. PubMed ID: 4022211
[TBL] [Abstract][Full Text] [Related]
20. [Uptake of 86Rb by human erythrocytes: modification of the method and applications].
Albertini MC; Canestrari F; Galli F; Pascucci M; Galiotta P
Boll Soc Ital Biol Sper; 1992 Dec; 68(12):749-54. PubMed ID: 1339137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
